Loading...
India's potassium imports from PHILIPPINES total $10 across 1 shipments from 1 foreign suppliers. MSN LABS PHILIPPINES INC leads with $10 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include MSN LABORATORIES PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for potassium — a concentrated sourcing relationship with select suppliers from PHILIPPINES.
MSN LABS PHILIPPINES INC is the leading Potassium supplier from PHILIPPINES to India, with import value of $10 across 1 shipments. The top 5 suppliers — MSN LABS PHILIPPINES INC — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MSN LABS PHILIPPINES INC | $10 | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MSN LABORATORIES PRIVATE LIMITED | $10 | 1 | 100.0% |
PHILIPPINES → India trade corridor intelligence
As of April 2026, the Philippines to India trade corridor is experiencing moderate port congestion at major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra. Sea freight transit time averages 7 days, while air freight takes approximately 3 days. Freight rates have remained stable over the past year, and the exchange rate between the Indian Rupee (INR) and the Philippine Peso is favorable for trade.
The Indian government's self-reliance initiatives, including the Production Linked Incentive (PLI) scheme, aim to boost domestic manufacturing of pharmaceutical products. While these policies encourage local production, they also impact imports of finished formulations, including those from the Philippines. Import substitution policies are being implemented to reduce dependency on foreign imports, which may affect future import volumes.
India and the Philippines maintain strong bilateral trade relations, with ongoing negotiations for a Free Trade Agreement (FTA) to facilitate smoother trade processes. Mutual recognition of Good Manufacturing Practices (GMP) is being pursued to enhance the quality and safety of pharmaceutical products traded between the two countries. These efforts aim to streamline customs procedures and promote pharmaceutical trade.
The landed cost for importing finished potassium formulations from the Philippines to India includes the following components:
A detailed per-unit estimate requires specific product details and current rates.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing potassium into India, the foreign manufacturer must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The product must be registered with the Central Drugs Standard Control Organisation (CDSCO), which involves submitting Form CT-20/40/41, along with a No Objection Certificate (NOC) from the manufacturer. The registration process typically takes 6 to 12 months. Specific requirements for potassium formulations under HS Code 30041090 include providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data compliant with ICH Zone IV standards.
Imported batches of potassium formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data must demonstrate a shelf life suitable for India's climatic conditions. Port inspections by customs drug inspectors are mandatory to ensure product quality and safety.
In January 2026, the Indian government imposed import restrictions on certain pharmaceutical ingredients, including Penicillin G-potassium, 6-APA, and Amoxicillin Trihydrate, for one year. These restrictions apply to imports with a CIF value below specified thresholds and aim to promote domestic manufacturing. The restrictions do not affect imports by 100% export-oriented units, units in Special Economic Zones, or imports under the advance authorization scheme, provided the imported inputs are not sold into the domestic tariff area.
Market demand, customs duty structure, and competitive landscape · Import duty: 17.10%
India imports finished potassium formulations to meet the demand for specific dosage forms and patented or branded products not manufactured domestically. The market size for potassium formulations in India is substantial, with a total export market of $642.2 million across 877 exporters to 177 countries. This indicates a significant demand for potassium formulations, both for domestic use and export.
The total landed duty for importing finished potassium formulations under HS Code 30041090 into India is 17.10%. This includes a 10% Basic Customs Duty, 2% Education Cess, 1% Secondary Higher Education Cess, and 6% Countervailing Duty (CVD). Additionally, the Social Welfare Surcharge (SWS) is 10%, and the Integrated Goods and Services Tax (IGST) is applicable based on the product's classification. Anti-dumping duties and exemption notifications may apply depending on the specific product and country of origin.
India sources finished potassium formulations from the Philippines due to the availability of patented formulations, specialized dosage forms, and high-quality products. The Philippines offers competitive advantages in terms of cost and quality, making it an attractive source compared to other suppliers like China, Germany, and the United States. The Philippines holds a 15% share in India's pharmaceutical imports, indicating a strong position in the market.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports potassium formulations from the Philippines due to the availability of specialized dosage forms, patented products, and high-quality manufacturing standards. The Philippines offers formulations that may not be produced domestically, fulfilling specific market needs in India.
Compared to other sources like China, the European Union, and the United States, the Philippines offers competitive pricing, quality products, and favorable trade relations with India. The Philippines's unique advantage lies in its ability to provide specialized formulations and maintain high manufacturing standards.
Potential risks for Indian importers include reliance on a single source, currency fluctuations, regulatory changes, quality control issues, and shipping disruptions. Past shortages have been minimal, but it's advisable to monitor the supply chain regularly to mitigate potential risks.
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Potassium suppliers from PHILIPPINES to India include MSN LABS PHILIPPINES INC. The leading supplier is MSN LABS PHILIPPINES INC with import value of $10 USD across 1 shipments. India imported Potassium worth $10 USD from PHILIPPINES in total across 1 shipments.
India imported Potassium worth $10 USD from PHILIPPINES across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Potassium sourced from PHILIPPINES include MSN LABORATORIES PRIVATE LIMITED. The largest buyer is MSN LABORATORIES PRIVATE LIMITED with $10 in imports across 1 shipments.
The total value of Potassium imports from PHILIPPINES to India is $10 USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists